Compare TransMedics Group Inc (TMDX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Tripadvisor Inc Common Stock — how do they compare? TransMedics Group Inc trades at $86.65 (market cap $3.10B), while Tripadvisor Inc Common Stock trades at $10.54 (market cap $1.28B). The key difference: TransMedics Group Inc is far larger — about 2.4× Tripadvisor Inc Common Stock's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| TMDX | TRIP | |
|---|---|---|
Market Cap | $3.10B | $1.28B |
Sector | Technology | Consumer Cyclical |
52-Week High | $150.42 | $19.14 |
52-Week Low | $61.99 | $9.24 |
Enterprise Value | $3.49B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Tripadvisor (TRIP) trades at $10.78, flat on the day, with a bearish technical signal but bullish oscillators. The company reported Q2 2026 EPS of $0.35, missing estimates, though revenue reached $1.89B in 2025 with a net income margin of 2.11%. Recent news highlights competitive pressures from AI travel tools and the pending $700M sale of TheFork to American Express, providing a cash infusion.
Outlook remains mixed; the stock is undervalued on P/S (0.72) but carries a high P/E (127.18). Risks include stiff competition and earnings misses, yet analyst consensus targets $13.29, suggesting 23% upside. Investor sentiment is cautious, with 62.5% hold ratings, but Viator's U.S. leadership offers a growth avenue amid challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
